RenovoRx AI Stock Analysis
Want to see RNXT full AI Analyst Report?
RenovoRx (RNXT) AI Stock Analysis
RenovoRx
(NASDAQ:RNXT)
The score is held down primarily by weak financial performance driven by large ongoing losses and heavy cash burn despite improving revenue and strong gross margins. Technical indicators also point to weak intermediate momentum. Offsetting these, the earnings call signaled solid commercial traction, maintained guidance, and meaningful clinical progress (Phase III enrollment complete), while regaining Nasdaq compliance reduces a key listing-risk overhang.
RenovoRx (RNXT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $58.87M
- Dividend Yield
- ―
- Average Volume (3M)
- 823.18K
- Price to Earnings (P/E)
- -3.9
- Beta (1Y)
- 0.91
- Revenue Growth
- 199.14%
- EPS Growth
- 12.75%
- Country
- US
- Employees
- 17
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
RenovoRx Business Overview & Revenue Model
Company Description
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arte...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, RenovoRx has not established a mature, recurring commercial revenue base from product sales; publicly available information indicates it is primarily in the research and development phase, advancing its...
RenovoRx Earnings Call Summary
The call was predominantly positive, with record revenue, strong sequential and year-over-year growth, expansion in active commercial centers and the sales pipeline, completion of Phase III enrollment, new clinical evidence, broader use cases and a maintained revenue outlook. The company continues to report net losses and higher selling, general and administrative expenses, while the impact of emerging pancreatic cancer therapies remains uncertain, but these challenges were outweighed by the reported commercial and clinical progress.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
RenovoRx is maintaining its full year 2026 revenue guidance of $3.75 million to $4.25 million and remains confident in its ability to meet its year-end 2026 target of 36 active commercial cancer center customers; it expects initial top line data from the Phase III TIGeR-PaC trial in the second half of 2027, believes its cash position provides sufficient runway to fund operations into the second half of 2027, expects operating losses to narrow further as it advances towards its goal of sustained profitability, and continues to work towards its goal of cash flow positive operations.
RenovoRx Financial Statement Overview
Summary
Revenue is improving (TTM ~$2.8M, ~+40%) with strong gross margins (~84%), but the company remains deeply unprofitable (TTM net loss ~-$13.0M) and is consuming significant cash (TTM operating cash flow ~-$12.1M; free cash flow ~-$12.2M). The balance sheet has low debt (~$0.2M) and improved equity (~$9.3M), but ongoing losses and burn remain the dominant financial risk.
Income Statement
34NegativeBalance Sheet
62PositiveCash Flow
29Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.78M | 1.12M | 43.00K | 0 | 0 | 0 |
| Gross Profit | 2.33M | 796.00K | 43.00K | 0 | 0 | 0 |
| EBITDA | -12.60M | -11.17M | -8.81M | -10.12M | -9.83M | -5.48M |
| Net Income | -13.02M | -11.17M | -8.81M | -10.23M | -9.89M | -6.32M |
Balance Sheet | ||||||
| Total Assets | 12.44M | 8.10M | 8.12M | 1.47M | 7.26M | 16.29M |
| Cash, Cash Equivalents and Short-Term Investments | 10.40M | 7.02M | 7.15M | 1.17M | 6.44M | 15.19M |
| Total Debt | 225.00K | 212.00K | 278.00K | 0 | 0 | 0 |
| Total Liabilities | 3.15M | 2.67M | 3.64M | 4.47M | 1.10M | 938.00K |
| Stockholders Equity | 9.28M | 5.42M | 4.48M | -3.00M | 6.16M | 15.35M |
Cash Flow | ||||||
| Free Cash Flow | -12.22M | -10.97M | -9.14M | -10.26M | -8.81M | -5.93M |
| Operating Cash Flow | -12.13M | -10.97M | -9.13M | -10.26M | -8.81M | -5.92M |
| Investing Cash Flow | -90.00K | -2,000 | -12.00K | 2.03M | -2.03M | -15.00K |
| Financing Cash Flow | 12.59M | 10.85M | 15.12M | 5.01M | 42.00K | 19.33M |
RenovoRx Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNXT, the sentiment is Negative. The current price of 1.22 is below the 20-day moving average (MA) of 1.26, below the 50-day MA of 1.50, and above the 200-day MA of 1.11, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 44.12 is Neutral, neither overbought nor oversold. The STOCH value of 46.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNXT.
RenovoRx Risk Analysis
RenovoRx disclosed 73 risk factors in its most recent earnings report. RenovoRx reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksRenovoRx Peers Comparison
Overall Rating
- RNXT48Neutral
XLO41Neutral
KPTI40Underperform
IMMP39Underperform
TCRX37Underperform
RADX29Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| RNXT | 48Neutral | $56.94M | -3.86 | -149.01% | ― | 199.14% | 12.75% |
| XLO | 41Neutral | $56.13M | -33.88 | -18.51% | ― | 72.97% | 97.20% |
| KPTI | 40Underperform | $394.66K | 0.00 | 77.63% | ― | 6.81% | 11.95% |
| IMMP | 39Underperform | $24.23M | -0.46 | -98.86% | ― | ― | -33.93% |
| TCRX | 37Underperform | $12.55M | -0.20 | -108.72% | ― | 2.15% | 17.34% |
| RADX | 29Underperform | $12.91M | -0.26 | -144.24% | ― | -19.76% | 8.58% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RNXT | Renovorx, Inc. | 1.22 | 0.25 | 25.26% | |
| IMMP | Immutep | 3.56 | -33.24 | -90.33% | |
| KPTI | Karyopharm Therapeutics INC | 0.02 | -5.48 | -99.69% | |
| TCRX | Tscan Therapeutics, Inc. | 0.18 | -0.94 | -83.63% | |
| XLO | Xilio Therapeutics Inc | 8.47 | -1.35 | -13.76% | |
| RADX | Radiopharm Theranostics Limited Sponsored ADR | 0.82 | -3.72 | -81.94% |
RenovoRx Corporate Events
RenovoRx Regains Nasdaq Compliance on Minimum Bid Price
PositiveOn December 31, 2025, RenovoRx, Inc. received notice from Nasdaq that it was not in compliance with the exchange’s minimum bid price rule because its common stock had closed below $1.00 per share for 30 consecutive business days. This noncompliance p...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026